10 Best Stocks Under $10 to Watch in 2025

Finding decent stocks for under $10 can be a challenge. There are often very good reasons that a stock will be trading that low and few of them are good. However, there can be some finds in the bargain bin of stocks, sometimes called “penny stocks,” though that term is usually reserved for stocks that are below $5 a share. 

It’s worth noting that less than five years ago, Nvidia (NASDAQ: NVDA) was trading below $5 a share, and six years ago, Super Micro Computer (NASDAQ: SMCI) was trading for less than $10 a share. Now, both trade in the triple digits, even after stock splits. We compiled a list of 10 stocks that have the potential for a breakout.

An in-depth look at these stocks under $10 with high potential

Let’s see a deeper analysis of why we like these 10 stocks that trade at or under $10. We found strong potential for all 10 companies, with all of them displaying revenue growth and improved profitability.

1. SuperCom: Locking up monitoring contracts with governments

SuperCom’s recent surge of new contracts for its PureSecurity Suite solutions has the stock up more than 149% over the past year. It also has encouraged investors by its recent efforts to pay down its debt, even if that means a little dilution for the stock’s price. The company’s biggest focus is on offender electronic monitoring systems.

The high cost of housing inmates, particularly in the US, has led to a greater use of offenders being placed under house arrest, monitored by SuperCom’s systems. Its monitoring systems are used for monitoring in cases of domestic violence, inmate monitoring, alcohol monitoring and in various rehabilitation services.

Through the first nine months of 2024, it reported net income of $2.52 million, compared to a loss of $2.48 million in the same period in 2023. Revenue grew by nearly 2% to $21.3 million during that period, and gross profit margin improved to 50.1% from 37.7% in the same period in 2023.

SuperCom’s shares got a bump when it landed the National Israeli Electronic Monitoring project. The company has also expanded with contracts into new regions, including New York, West Virginia, and Maryland. Because of the hurdles to getting government contracts, it has relatively few competitors.

_{Your capital is at risk.}

2. Valley National Bancorp: Seeing higher margins, still attractively valued

Regional banks have struggled in recent years but Valley National Bancorp, the holding company for Valley National Bank, appears to have turned the corner by improving its margins significantly. Its price to earnings ratio (P/E) is less than 14 times earnings, which also underscores the potential upside.

Valley reported encouraging fourth-quarter numbers. Its revenue was $474.2 million, compared to $449.9 million in the fourth quarter of 2023. Earnings per share rose to $0.20, compared to $0.13 in the same period a year ago. It also maintained its quarterly dividend of $0.11, equaling an enticing yield of 4.58%.

The company beefed up its C-suite experience recently with the appointment of Gino Martocci as Senior Executive Vice President, President of Commercial Banking and Travis Lan as Senior Executive Vice President, Chief Financial Officer (CFO). Martocci, who came over from M&T Bank, where he was head of its commercial banking business for the past eight years, has more than 30 years of experience in banking and Lan was promoted from interim CFO.

_{Your capital is at risk.}

3. BGC Group: Additions to its services seem to be paying off

BGC, a leading global marketplace, data, and financial technology company specializing in trade execution across a broad range of products. It has enhanced its electronic trading abilities through acquisitions and new additions, including the development of new trading platforms such as FMX UST, FMX FX, and Fenics GO

In September, it started trading secured overnight financing rate (SOFR) futures on its new FMX Futures Exchange. The move puts it head-to-head with the Chicago Mercantile Exchange’s own futures exchange, which had a monopoly in the US.

The company has consistently shown double-digit growth. In fiscal 2024, it reported revenue of $2.26 billion, up 12% and EPS of $0.25, up 257%. For the first quarter of 2025, it is estimating revenue between $610 million and $660 million, compared to $578.6 million in the first quarter of 2024. It also said it expects quarterly pre-taxed adjusted earnings to be between $145 million and $161 million after seeing $135.4 million in the period a year ago.

The Trump Administration’s focus on deregulation could also benefit BGC’s new FMX Futures Exchange.

_{Your capital is at risk.}

4. SIGA Technologies: Increased sales, markets and dividend

The pharmaceutical company, which specializes in treating and preventing biothreats, is seeing growing sales for its TPOXX smallpox vaccine. In October, it made its first commercial sale of the drug in Africa when Morocco sought a way to slow an mpox outbreak. TPOXX was already approved in the US and Canada and is authorized in Europe and the UK to treat smallpox, mpox, cowpox and complications from vaccinia virus.

The stock is down more than 14% so far this year and it is trading for less than five times earnings.  Most of the company’s business stems from US government contracts to stockpile TPOXX as a smallpox vaccine. However, the company has shown that TPOXX is effective in fighting other communicable diseases.

Through the first nine months of 2024 , revenue was up 145% year over year to $53.5 million, and EPS was $0.19, compared with an loss per share of $0.06 in the same period last year. The company is still quite reliant on its only approved therapy and its business is cyclical, but still, its shares appear underpriced considering its earnings. Also, for a relatively small company, it has a high-yield dividend of 10.35%.

_{Your capital is at risk}

5. AdaptHealth: Improved profitability, steady revenue growth

AdaptHealth is well-positioned for growth because of a number of trends. Our aging population calls for more medical spending and the rising costs of healthcare are pushing more care out of hospitals and clinics and into the home.

In fiscal 2024, the company saw mild revenue growth, but a big jump in margins. It reported yearly revenue of $3.261.0 billion, up 1.9% and net income of $90.4 million compared to a loss of $678.9 million in 2023.

There are an estimated 1 billion people worldwide with sleep apnea and thanks to increased levels of obesity, particularly in Western nations, it’s likely to rise. Adapt Health sees nearly 60% of its products come treatments for respiratory conditions, including sleep apnea.

The company, even after a bump in share price this year, trades for less than 15 times earnings. AdaptHealth is predicting steady, if modest, revenue growth this year of between $3.22 billion to $3.36 billion, but its guidance for adjusted earnings before interest, depreciation, taxes and amortization (EBITDA) is between $670 million to $710 million, compared to $688.7 million in 2024.

_{Your capital is at risk.}

6. AIA Group: Dominance in Asia bodes well for continued growth

AIA Group may benefit from US tariffs against China as they may mean more business for other countries in Southeast Asia. The company provides life insurance and financial services in Hong Kong, Thailand, Singapore, Malaysia, mainland China, and other markets.

AIA Group has set records for value of new business (VONB) in each of the first three quarters. In the third quarter, it reported VONB of $1.16 billion, up 17% year over year, with all of its segments seeing improved results. It also said it annualized new premiums jumped 14% compared with the same period last year to $2.2 billion.

The company is well-positioned for growth, thanks to its dominance in Asia, where the combination of improved savings, an aging population and relatively low insurance penetration offers strong opportunities for growth.

As a bonus, AIA also pays out a dividend that has a yield of 1.34%. The payout ratio is low at 16.74%, so there’s plenty of room for continued dividend growth.

_{Your capital is at risk.}

7. Rolls-Royce: Growing revenue, trimming costs

A little more than two years ago, Tufan Erginbilgic took over as the new CEO of the aerospace giant and the turnaround since then has been remarkable. The stock has doubled in value over the past five years and Erginbilgic has continued the work to make the company more efficient and pay down its debt. It ended 2024 with net cash of £475 million compared with net debt of £1.95 billion at the end of 2023.

In fiscal 2024, the company reported underlying revenue of £17.8 billion, up 15.8%, profit before taxation of £2.29 billion, up 81.7% and free cash flow of £2.43 billion, up 88.7%. The company pointed to continued expected growth this year, saying it expects free cash flow to be between £2.7 billion and £2.9 billion.

The company’s mid-term forecast (going to 2028) calls for double-digit margins in each of its segments, led by civil aerospace to be between 18% and 20%, thanks to an outperformance from its large engine aftermarket performance. It also points to 14% to 16% margins from power systems, thanks to increased data center needs and 14% to 16% margins from its defense segment.

While its shares have risen more than 48% so far this year, it remains a decent value stock. It also announced, after a hiatus during the COVID-19 pandemic, that it will pay a dividend of 6 pence per share. The company also launched a £1 billion share buyback program.

_{Your capital is at risk.}

8. StepOne Clothing: Focusing on the bottom line

StepOne has succeeded by doing one thing well — making underwear. The Australian company, founded in 2017, focuses on making environmentally friendly undergarments. The company has no debt and has systematically been growing its bottom line.

It also doesn’t mess around with retail stores as all of its business is done online. Already an established player in Australia, it grew its business last year with a partnership with John Lewis in the UK. It’s also making a big effort to sell to the US through Amazon.

In fiscal 2024, it reported preliminary revenue of AUD $84.5 million, up 29.7% with net profit of AUD $12.4 million, up 43.9%. Much of that growth was from the company’s women’s line, which was launched in 2022. The company’s sales of women’s underwear in fiscal 2024 was listed at $11.1 million, up 54%.

In the first half of fiscal 2025, the company continued to see improvement. It had sales of AUD $48.12 million, rising 6.8% year over year, and net income of AUD $8.18 million, up 15% from the same period last year. One concern is that sales in the US dropped because StepOne cut back on advertising in the US to retain margins.

The stock also has a twice-yearly dividend that yields 7.62% and is fully franked. It just raised its interim dividend by 10% to AUD 4.4 cents.

_{Your capital is at risk.}

9. Haleon: Leaner but still a leader in commercial healthcare products

The company, which was spun off from GSK in 2022 and is partially owned (7%) by Pfizer, is one of the largest consumer healthcare companies in the world. Haleon has narrowed its focus in recent years to improve its profitability, dropping non-performing brands and trimming its number of distribution centers and warehouses.

In fiscal 2024, the company reported a pretax profit of £1.91 billion, up 17.1%. Revenue was down 0.6% to £11.23 billion, which Haleon chalked up to currency headwinds. Looking forward, it reiterated its guidance for the medium term of 4% to 6% and said it expects organic revenue growth in the range of 4% to 6% this year, with operating profit growth expected to be above that range.

Haleon also raised its final dividend to 4.4 pence, up 9.5% over the prior year. Its dividend yield is a slightly-above-average 1.59%.

_{Your capital is at risk.}

10. Verb Technology: Changing directions, paying down debt

Verb sees itself as a disruptor in the crowd-funding category. It has produced MARKET.live, a livestream social shopping platform that could benefit significantly from the demise of TikTok. It also sponsors GO FUND YOURSELF!, an interactive TV show and new platform that features start-up companies.

Through the first nine months of 2024, Verb’s revenue rose 341% year over year to $172,000. It’s notable that 75% of that revenue came in the three months that ended Sept. 30, led by its new MARKET.live and Go Fund Yourself units. The company sold its SaaS assets for $6.5 million, allowing it to concentrate on MARKET.live and its Go Fund Yourself business unit and pay down its long-term debt. Through nine months, it reported a net loss of $7.14 million, compared to a $19.1 million loss in the first three quarters of 2023.

The company’s small size makes it risky but also means its shares could jump if it continues to grow. It completed a 1-for-200 reverse stock split last year to regain its NASDAQ listing.

_{Your capital is at risk.}

Year-to-date performance of the top stocks under $10 in 2025

_{Your capital is at risk.}

---

What sectors offer stocks with a price tag under $10 most often?

There’s no single sector where stocks are under $10, as low-priced stocks are in nearly every sector. However, exploratory mining stocks, cutting-edge technical stocks and regional banks are the most likely sectors to have stocks with shares under $10. That’s because those companies tend to have lower market capitalizations, and those sectors have more companies without a proven track record to warrant a higher share price. 

Regional banks, such as Valley National Bancorp often have lower share prices because they have a hard time competing against national or international banks. Mining stocks, such as Kinross Gold, often have lower-priced shares because mining as a sector has higher risks than other sectors and start-up technology stocks, such as Clover Health or LegalZoom, are often priced below $10 because they haven’t shown consistent profitability.

How t​​o add cheap US stocks to your portfolio

It isn’t hard to invest in US stocks, whether you live in the US or elsewhere. The basic steps start with choosing a brokerage that offers access to US markets. When making your shortlist, consider factors like fees, selection of stocks and funds, educational resources, and ease of use. It’s also worth noting that not all brokerage firms allow investors to buy so-called penny stocks, those that trade under $5 a share. Once you find a broker, open an account, providing the necessary personal and financial information and choose an account type. From there, all you have to do is fund the account and convert the funds to US dollars if necessary. Then pick the right US stocks after doing your research.

---

How to spot inexpensive stocks that have high potential 

Identifying inexpensive stocks with high potential requires a combination of research, analysis, and risk assessment. Some steps you can take:

Use a stock screener to find low-priced stocks: A stock screener can help investors find stocks below $10 and then can be used to compare those stocks to others in their industries. There are also stock predictor services that can help you find quality stocks under $10.

Focus on Growth: Stocks trading under $10 typically represent smaller, newer companies with higher volatility and risk compared to larger, more established stocks. However, they can offer significant growth potential if you’re willing to do your due diligence.

Prioritize Sustainable Growth: When evaluating stocks under $10, focus on companies with a clear path to profitability and sustainable growth. Even if they’re not currently profitable, their business model should demonstrate potential for future earnings.

Identify a Competitive Advantage: Look for companies with a unique business model or competitive advantage that sets them apart from competitors. This could be a proprietary technology, a strong market position, or a unique customer base.

Consider Undervalued Companies: Many promising stocks under $10 may be overlooked by investors due to their smaller size or lack of consumer recognition. These companies can offer significant value if they have solid financials and a strong business model.

Do your financial homework: Examine a company’s earnings reports to assess its financial health, profitability and debt levels. Understand its valuation ratios, such as price-to-earnings (P/E) that might show if it is undervalued compared to its peers.

Understand trends: The growing need for lithium for EVs, for example, bodes well for Arcadium Lithium. The rising price of gold is a trend that helps Kinross Gold. The growing use of internet technology helps Clover Health, LegalZoom, Coursera and SoFi Technologies.

Know the risks: Is the company carrying a lot of debt? Is whatever moat the company has sustainable? How much capital does the company have to withstand an economic downturn? It also makes sense to understand your own level of risk. If you are looking at lesser-priced stocks that may have a higher level of volatility, is the rest of your portfolio set up with more established stocks for diversification?

---

Pros and cons of buying stocks costing less than $10 

Investing in any stock requires some level of risk tolerance by an investor. Stocks that trade below $10, indeed, carry more risk than larger companies with higher share prices. Here are a few pros and cons of buying stocks that cost less than $10.

Some of the pros of stocks below $10

Potential for High Returns: Due to their lower valuations, stocks under $10 can offer significant upside potential if the company experiences growth or increased investor interest. It’s worth remembering that many of today’s largest companies once started out trading at less than $10 a share.

Accessibility: Investing in stocks under $10 can be more accessible to those with limited capital, as smaller investments can still yield meaningful returns. Obviously, it’s a lot easier to buy 100 shares of a stock that trades under 10 dollars a share than in a stock whose shares cost more than $100 a share.

Undervalued Opportunities: Some stocks may be trading below their intrinsic value, offering potential buying opportunities for patient investors. 

Some of the cons of investing in stocks below $10

Increased Risk: Stocks under $10 often have higher volatility and are more susceptible to market fluctuations. That’s not necessarily a bad thing, but it can cause stress for investors.

Limited Liquidity: Trading volume for these stocks may be lower, making it difficult to buy or sell shares quickly. If you buy a stock for under $10 and later have buyer’s remorse, you may have to sell the stock at a loss.

Higher Risk of Fraud: Penny stocks, a subset of stocks under $10, are often associated with higher risks of fraud and manipulation. When a stock’s shares are below $10, it is easier to have  a larger percentage move.

Lack of Information: Smaller companies, with smaller marketing departments, may have less public information available, making it more challenging to assess their financial health and prospects.

Summary of the benefits and drawbacks of US stocks available for under $10

Methodology: How we chose the stocks under $10 on our list

We spent a lot of time figuring out the best stocks under $10. Investing in lower-priced stocks often means a greater risk, so we vetted these stocks with care, knowing that buying them would still entail a certain level of risk. The factors we looked at:

• Downtrodden stocks: We looked for companies whose shares have fallen this year, looking for companies who may be oversold at this point. Most of the stocks on our list have seen their shares drop by double-digit levels so far this year, led by a 63% fall by Arcadium Lithium.
• Stocks on the rise: On the other hand, we also looked for companies that are still below $10 despite significant momentum, such as Clover Health, Kinross Gold and SoFi Technologies.
• Profitability: We looked for companies that were either turning a profit or at least appeared to be closer to profitability.
• Revenue growth: One of the biggest factors we focused on were companies whose revenue growth, year over year, in their most recent quarter.
• Competitive advantages: We looked for companies that serve a somewhat unique niche, such as Coursera, Clover Health or LegalZoom, which gives them certain first-to-market advantages.

---

Benzinga Pro – Track the stock market with this top research software

Benzinga Pro is the ideal financial research platform to leverage when looking to identify your potential stock investment opportunities. This financial news and data platform is tailored for active and high-volume traders, especially those monitoring US stock markets. It delivers fast, actionable market insights, allowing traders to react instantly to breaking news, corporate releases, and chart signals. 

The platform’s standout feature is its customizable real-time news feed, which sources information from in-house journalists, PR Newswires, SEC filings, and partners like Reuters. Its patented price sentiment engine indicates the likely direction of a stock’s movement based on news, making it a valuable tool for traders.

Benzinga Pro’s Audio Squawk broadcasts key market updates and headlines, while its detailed charts and over 100 technical indicators, such as Bollinger Bands and Fibonacci retracements, assist in decision-making.

Subscriptions range from $37 to $197 per month, with a 14-day free trial for its Essential plan, making it a strong option for frequent traders.

---

FAQs on inexpensive stocks